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Abstract 
A series of 47 structurally diverse MGBs, derived from the natural product distamycin, was evaluated 
for anti-lung cancer activity by screening against the melanoma cancer cell line B16-F10. Five 
compounds have been found to possess significant activity, more so than a standard therapy, 
Gemcitabine. Moreover, one compound has been found to have an activity around 70-fold that of 
Gemcitabine and has a favourable selectivity index of greater than 125. Furthermore, initial studies 
have revealed this compound to be metabolically stable and thus it represents a lead for further 
optimisation towards a novel treatment for lung cancer.  
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Cancer is a major health problem responsible for approximately 13 % of the deaths worldwide. The 
incidence is estimated to be around 13 million cases a year, according to WHO.1 In particular, lung 
cancer is one of the most frequent cancers causing around 1.4 million deaths per annum. The 
treatment of lung cancer is based on chemotherapy and/or surgery. However, surgery is limited to 
those tumours with peripheral location. Other types of tumours with a more difficult access, such as 
small-cell lung cancer, are generally treated with chemotherapeutic agents. A first-line 
chemotherapy treatment is a platinum based combination of cisplatin or carboplatin with etoposide 
or irinotecan.2 The mechanism of action of platinum based compounds is localised at the major 
groove of the DNA where the drug interferes with the genetic transcription. These modifications 
result in variations in the product from crucial genes involved in cell-cycle replications and finally 
induce cell apoptosis. Nonetheless, treatment with many traditional anticancer drugs, such as 
cisplatin, is related to drug resistances and unsuccessful therapeutic outcome. Therefore, the need 
of new anticancer compounds that could overcome those resistances by binding to the smaller 
groove of the DNA.3  
 
Minor Groove Binders (MGBs) are a class of compound that specifically, and reversibly, bind to the 
minor groove of DNA. They recognise specific base sequences of DNA with high selectivity and 
achieve efficacy by interfering with transcription factors and altering gene expression.4 
Our approach at the University of Strathclyde has been to diversify the structure of the first 
discovered MGB, distamycin, and to generate a portfolio of significantly active Strathclyde Minor 
Groove Binders (S-MGBs). We can now design novel S-MGBs with tailored activities through a 
detailed understanding of DNA binding, sequence selectivity, and physicochemical characteristics 
(figure 1). 
  
 
Figure 1. Distamycin and our lead Gram-positive antibacterial compound, MGB-BP-3. 
Deviations from the distamycin structure have included tuning the basicity (pKa) of the tail group 
amidine at the C-terminus, the addition of larger alkyl side chains and the introduction of thiazole 
rings. Aromatic rings replaced the distamycin formyl group and, importantly, the N-terminal amide 
was replaced by its isosteric alkene.5 These structural changes systematically modified the 
physicochemical properties to increase hydrophobic contacts with the target DNA resulting in a 
library of highly potent compounds displaying distinct biological activities. The physicochemical 
aspects of this design hypothesis were investigated in detail and shown to lead to strong DNA 
binding driven largely by enthalpic interactions.6 Furthermore, studies suggest that the 
physicochemical properties of MGBs substantially determine their net uptake into target cells. Our 
knowledge in this area has led to the discovery of a family of compounds with significant anti-Gram-
positive bacterial activity, the most active of which, MGB-BP-3, has successfully completed Phase I 
clinical trials for the treatment of Clostridium difficile infections. Furthermore, other S-MGBs have 
been shown to be active against Trypanosoma both in cell-based studies and in mouse models of 
disease and leishmaniasis.7 
 
Distamycin itself does not possess significant cytotoxicity; however, other classes of MGB have 
displayed significant potential as anti-cancer agents, most notably those which are directly derived 
from the distamycin framework. Tallimustine (figure 2) in which the formyl head group of distamycin 
has been replaced with a benzoic acid mustard (BAM) moiety displays high activity against various 
murine tumors and human xenografts. Most other BAM compounds alkylate and cross-link within 
DNA’s major groove; however, with the minor groove binding affinity conferred by the distamycin 
framework, tallimustine has been shown to preferentially monoalkylate the 3’-adenine-N3 atom of 
5’-TTTTGA-3’ sequences in the minor groove.8 In distamycin type molecules, increasing the number 
of pyrroles is linked to an increase in DNA binding affinity and this is true of tallimustine where an 
increase to four pyrroles significantly increases the cytotoxicity.9,10 Development of tallimustine was 
promising as phase I and II clinical trials demonstrating significant antitumor, but notably 
myelotoxicity led to the phase II clinical development being halted.11, 12, 13 
 
 
Figure 2. Tallimustine. 
As a class of compounds, S-MGBs are not inherently cytotoxic:  structural alterations away from that 
of distamycin led to anti-infective compounds with favourable selectivity indices.14 Despite the lack 
of class specific toxicity, some S-MGBs inhibit the growth of lung cancer cells. This paper describes 
the evaluation of a panel S-MGBs as potential lung cancer therapeutics. 
The compounds synthesised for this investigation are typical of S-MGBs in general. They include 
compounds with amide, amidine, or alkene linked head groups with a range of polar and non-polar 
  
features, N-alkyl pyrroles, a standard feature of minor groove binders, C-alkyl thiazoles, a specific 
feature of S-MGBs, and tertiary amine tail groups with a variety of basicities (figure 3). These 
structural variations give rise to a set of compounds with a wide range of physicochemical properties 
and DNA-binding specificity. 
 
 
Figure 3. Exemplars of the structural variations in the S- MGB set investigated in this study. 
Synthesis of these MGBs was achieved in a modular fashion, initially building from the C-terminus, 
tail group end, of the molecule and ending with a coupling reaction to attach the head group. The 
synthesis of many of the compounds under study in this letter has been published previously7 and 
that of the novel compounds can be found in the electronic supplementary information as the 
synthetic methods are similar. 
All MGBs were purified by HPLC to give a final purity greater than 98%. Table 1 shows the structures 
of the MGBs that were investigated in this study. 
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Table 1. S-MGBs evaluated in this study 
In this study the melanoma cancer cell line B16-F10, which quickly metastases to the lungs, was used 
for initial screening. This cell line was derived from pulmonary metastatic cells isolated from the 
lungs of mice after ten successive passages of B16 sub-lines.16 The original B16-F10 cell line was 
transfected with firefly luciferase gene to develop the B16-F10-luc murine melanoma cell line 
(Bioware® B16-F10-luc-G5, Caliper Life Sciences; Hopkinton, USA). The integration of this gene allows 
disease progression to be monitored by luciferin-luciferase bioluminescence imaging.17 46 
compounds from the S-MGB library were tested at a single concentration of 15 µg/mL for their 
ability to inhibit the growth of B16-F10-luc cells. The bioluminescence emitted from the cells treated 
with MGBs was compared to the bioluminescence emitted for the solvent control cells to establish a 
baseline (Table 2). 
S-MGBs have been extensively investigated as anti-infective agents, initially as antibacterial and 
more recently as antiparasitic agents.7 Two key properties of S-MGBs characterize their biological 
activity, namely DNA binding and access to cells. Most S-MGBs are based on the distamycin structure 
and thus possess an affinity towards DNA binding; however, it is access to cells that has been found 
to be the most important factor explaining activity, and selective toxicity. For example, S-MGBs 
possess very strong anti-Gram-positive activity but little anti-Gram-negative activity and this appears 
principally to be due to efflux from Gram-negative cells. Since S-MGBs show anti-Gram-negative 
activity in the presence of efflux pump inhibitors it is possible that efflux is the chief cause of the lack 
of activity in this class of bacteria. The action of efflux pumps on S-MGBs appears to be related to 
their physicochemical properties and it is thus likely that these will be important in explaining anti-
lung cancer activity. To this end, logD7.4 was predicted using the software MarvinSketch (Version 
15.6.29.0, ChemAxon, http://www.chemaxon.com), in an attempt to gain some insight into the 
differences in activity. These results, alongside the activity data, are presented in table 2. 
MGB Inhibition  
(% ± SD) 
LogD7.4 MGB Inhibition 
(% ± SD) 
LogD7.4 MGB Inhibition  
(% ± SD) 
LogD7.4 
1 NA  0.18 17 46 ± 0.43 4.11 33 88 ± 3.1 *** 4.50 
2 NA -2.42 18 37 ± 17 4.11 34 55 ± 26 3.92 
3 NA 2.77 19 NA 4.11 35 55 ± 24 4.06 
4 53 ± 7.3 6.51 20 NA 2.59 36 69 ± 14** 4.56 
5 NA 7.56 21 NA 1.08 37 57 ± 2.5 * 0.93 
6 NA 1.90 22 NA 3.86 38 2.2 ± 6.9 1.27 
7 NA 0.80 23 77 ± 5.7 * 4.85 39 72 ± 4.4 ** 4.37 
8 40 ± 26 4.97 24 34 ± 4.7 2.29 40 59 ± 13 * 3.26 
9 NA 0.56 25 NA 3.81 41 76 ± 5.1 ** 4.24 
10 19 ± 47 4.99 26 44 ± 10 2.83 42  74 ± 12** 2.95 
11 57.12 ± 11.48 * 2.22 27 34 ± 5.4 3.41 43 NA -1.74 
12 30.92 ± 28.62 3.15 28 83 ± 3.5 *** 3.51 44 NA -1.13 
13 16.13 ± 8.45 2.39 29 84 ± 3.4 *** 4.04 45 NA -0.48 
14 NA 3.15 30 84 ± 3.8 *** 4.04 46 67 ± 12 0.50 
15 NA 1.48 31 85 ± 2.9 *** 3.51    
16 54.10 ± 9.16 3.81 32 77 ± 12** 2.12    
Table 2. The effect of treatment with different MGBs compounds on the proliferation of B16-F10-luc cells. Cells (3.7 x 105 
cells/well) were incubated for 24 hours in the presence of medium containing DMSO (solvent control, 2.44 % v/v DMSO) or 
  
different MGBs compounds (15.36 µg/ml with 2.44 % v/v DMSO). The effect of treatment on cell proliferation is shown as 
the mean percentage inhibition of n=3 experiments compared to the mean solvent control where NA is not active (* p ≤ 
0.05, ** p ≤ 0.01 and *** p ≤ 0.001 comparing bioluminescence of the cells treated with MGBs with the cells with solvent 
control). LogD7.4 predicted using the software MarvinSketch (Version 15.6.29.0, ChemAxon, http://www.chemaxon.com). 
The data shown in table 2 indicate that this selection of S-MGBs contains both significantly active 
and inactive compounds with respect to B16-F10 cells. It is significant that in this set of S-MGBs none 
of those bearing an amide linked head group has any appreciable activity against the B16-F10 cell 
line. Many of the inactive compounds in this set have shown appreciable activity against other 
disease targets: many have moderate antibacterial properties with MICs around 10 M; and, 45 has 
been shown to be significantly active in a mouse model of Trypanosoma congolense (manuscript 
submitted). This illustrates that the structure and physicochemical properties of S-MGBs influence 
their activity profiles against different organisms and cells. Compounds 34-41 represent a subset of 
short length S-MGBs having one pyrrole ring less than the others. A greater number of pyrrole rings 
usually correlates to greater DNA binding affinity and in many contexts greater activity; therefore, it 
is interesting to note that these shorter compounds still are active against B16-F10 cells. Moreover, 
this subset of compounds has been shown to in general to lack antibacterial activity, further 
evidence of differential activity profiles for S-MGBs (manuscript submitted).  
 
Figure 4. LogD7.4  vs % inhibition of B16-F10-luc cells. LogD7.4 predicted using the software MarvinSketch (Version 15.6.29.0, 
ChemAxon, http://www.chemaxon.com). Dotted box shows clustering of active compound around LogD7.4 range of 3-5. 
In an effort to explain the observed activities by considering the physicochemical properties of S-
MGBs, logD7.4, as a measure of lipophilicity, was plotted against the % inhibition of B16-F10-luc cells 
(figure 4). It is clear that lipophilicity, measured by logD7.4, alone cannot explain the activities of this 
set of S-MGBs; however, the most active compounds are clustered within a logD7.4 range of 3-5. The 
importance of lipophilicity is neatly explained through compounds 45, 44, 26 and 28-31, which all 
contain the same 4-methoxyphenyl-2-pyridylethenyl head group. 45 and 44 have basic amidine and 
dimethylamino tail groups, giving them very low logD7.4 values (-0.48 and -1.13, respectively) and no 
activity. The morpholino tail group in 26, with a logD7.4 of 2.83, gives a moderate activity of 44% 
inhibition and further increasing the lipophilicity by inclusion of a branched alkyl side chain (28-31, 
logD7.4 3.51 and 4.04) affords an excellent inhibition of around 84%. 
The % inhibition data was used to select a number of active compounds with a variety of structural 
features. For example, compound 28 was chosen to represent compounds 28 to 33 as these all 
  
possess the same core structure but differ in their alkyl side chain. The mean IC50 was determined for 
compounds 23, 28, 33 and 42 (table 3). In these studies, gemcitabine, a drug commonly used to treat 
cancer, was used as the positive control. 23, 28, and 33 had a smaller IC50 than gemcitabine (p ≤ 
0.05; Table 3) whereas 42 had similar activity to gemcitabine.  
MGB IC50 (µM ± SD) LogD7.4 
Gemcitabine 11.0 ± 1.7  ND 
23 0.16 ± 0.01 4.85 
28 0.81 ± 0.08 3.51 
33 1.1 ± 0.51 4.50 
42 10.4 ± 0.50  2.95 
47 2.2 ± 0.22  5.45 
Table 3. The mean half maximal inhibitory concentration (IC50) values for different MGBs compounds tested against B16-
F10-luc cells. The values shown are from three experiments and three replicates were used for each concentration tested in 
each experiment. 
Given the significant activity of compound 23, which contains an unusual trifluoromethyl 
substituent, the initial screening data were scrutinised for information that could prompt the design 
of a compound with greater activity. Compound 25 had no activity in the initial screen; however, 
compound 33, with an isopropyl instead of a methyl side chain, had an IC50 of 1.1 µM, highlighting 
the importance of this simple alteration. The isopropyl side chain also appears in compound 35, (IC50 
of 0.81 µM), and although its methyl side chain analogue, 26, was active (44% growth inhibition), 
there is still a substantial increase associated with the presence of the isopropyl group. This 
prompted the design of compound 47 which is an analogue of the most active compound, 23, but 
with the inclusion of the isopropyl side chain. However, 47 (IC50 of 2.16 µM) was 13-fold less active 
than 23. With the inclusion of the isopropyl group, the lipophilicity of compound 47 (logD7.4  = 5.45) 
is notably higher than that of 23 (logD7.4 = 4.85), suggesting that a logD7.4  less than 5 is required for 
optimal cellular activity. Nonetheless, with an activity approximately 70-fold greater than 
Gemcitabine, compound 23 is a significant find. Compound 23 has also been shown to have no 
appreciable activity in any of our routine screens against fungi, bacteria or parasites. Moreover, we 
have previously reported compound 23 to have no measureable toxicity against HEK cells at 20 µM 
thus giving a satisfactory selectivity index of >125.7 This discovery encouraged the further 
investigation of the biological action of S-MGBs in the context of anti-lung cancer therapeutics, in 
particular compound 23’s potential for further development. 
Minor groove binders that have seen use previously as anti-cancer agents are often modified with an 
DNA-alkylating moiety, such as in tallimustine. DNA binding is thus a plausible mechanism of action 
for this class of minor groove binder. In the case of other classes of minor groove binders, principally 
anti-infective agents including S-MGBs, an alternative mechanism of action has been suggested that 
involves cell membrane permeabilisation.18 S-MGBS that have strong affinities for DNA tend to also 
have strong antibacterial properties and more recently, we have found that significantly active S-
MGBs gain access to both bacterial cells and parasites, where nuclear localisation is observed.7 
However, penetration into mammalian cells has not yet been observed for any significantly active 
and non-toxic S-MGB that has undergone extensive investigation as anti-infective agents. To 
understand better the behaviour of S-MGBs in mammalian cells the strongly fluorescent probe S-
MGB (48) was used in fluorescence microscopy studies. 
  
 
Figure 5. Compound 48, A fluorescent probe S-MGB. 
To assess intracellular localisation in mammalian cells, B16-FO Luc cells were treated with 3 g/ml 
and 30 g/ml of compound 48, using 250 M Hoechst 33342 as a control, and were monitored for 
fluorescence using the UV and the DAPI filter sets.  
  
 
 
 
Figure 6. Fluorescence microscopy of B16/FO/Luc cells treated with S-MGB compound 48. Cells were exposed to various 
concentrations of the S-MGB for 1 hr and examined under an inverted fluorescent microscope using the X20 objective with 
brightfield and UV or DAPI filter sets. Row (a), 3 g/ml compound 48; (b), 30 g/ml compound 48; (c) DMSO only; (d), 250 
M Hoechst 33342.  Similar results were obtained in two experiments with separately prepared cells.   
There was clear evidence that compound 48 was internalised within the cells showing an increase in 
fluorescence with increasing concentration of the S-MGB. Comparison with the bright field image 
showed that fluorescence was concentrated in the nucleus, as observed for the positive control, 
Hoechst 33342. This assessment of a model, fluorescent S-MGB supports DNA binding as a plausible 
mechanism of action in mammalian cells. 
  
Knowledge of potential in vivo stability is a crucial indicator of whether or not a compound is 
suitable for further development in a drug discovery programme. The majority of drug metabolism 
takes place in the liver, so we carried out an assessment of rat hepatocyte uptake, and metabolism 
of compound 23 over a period of 24 h in primary monolayer cultures, and monitored cell viability 
over this time. There was no evidence of uptake of the drug into cells over the 24 h period when 
using red, green or blue filters for detecting fluorescence.  Although cell morphology showed no 
signs of overt toxicity (figure 7), fewer cells were consistently observed in drug treated dishes than in 
controls post-treatment.   
 
Figure 7. Phase contrast images of hepatocyte monolayers exposed to DMSO control (Left) and 7.5µM compound 23 for 60 
min (Right).   Zeiss Axiovision Fluorescence microscope, x 20 wet lens (N/A 0.5). There was no evidence of drug uptake 
during 24 h exposure using either green, red or blue filter settings. 
Aliqots of the medium of the hepatocyte incubations were extracted at 15 minutes, 60 minutes and 
24 hours and analysed by LC-MS in order to further assess the stability of these compounds and to 
identify any metabolites. Figure 8 shows the extracted ion trace for the 15 minute aliqot. 
  
   
Figure 8. Extracted ion traces for compound 23 and its hydroxy and dihydroxy metabolites (mets). 
Compound 23 showed only around 1% metabolism, estimated from the peak heights of the 
metabolites relative to the parent compound, over the 24-hour monitoring period of the 
experiment, the vast majority of this occurring within the first 15 minutes. The m/z of the 
metabolites are 665.2703 and 681.2653 and thus likely correspond to a mono and di-hydroxylated 
analogue of compound 23, which has a m/z of 649.2749. From these data, compound 23 can be 
concluded to be particularly stable over a sufficiently long time period to be deemed appropriate for 
further development. 
  
This study has indicated the importance of the activity profile of S-MGBs and serves to provide 
further evidence that subtle structural variations can influence the activity profiles of compounds 
within this class. A sub-set of S-MGBs has been identified which have significant activity against a 
lung cancer cell line, more so than a current treatment option, Gemcitabine. As a class, we have also 
demonstrated that a plausible mechanism of action for S-MGBs on mammalian cells is through DNA 
binding. 
These general findings have allowed us to select one compound, which is around 70-fold more active 
than Gemcitabine in our in vitro assay, and possesses a favourable selectivity index of >125 against 
the HEK cell line. Moreover, we have demonstrated its stability in a hepatocyte model and thus 
identified this compound as worthy for further development as an anti-lung cancer therapeutic. 
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Graphical abstract 
 
A distamycin derived minor groove binder with superior in vitro anti-lung cancer activity to 
Gemcitabine. 
  
  
 
Highlights 
 
Minor Groove Binders (MGBs) possess activity against the melanoma cancer cell line B16-F10. 
5 MGBs have been identified that have IC50s less than that of a standard therapy, Gemcitabine. 
A lead compound has been identified with activity around >70 times that of Gemcitabine and with a 
favourable selectivity index of >125. 
 
